
Mark A. Hlatky, MD
Professor of Health Research and Policy and of Medicine (Cardiovascular Medicine) and CHP/PCOR FellowDepartment of Health Research and Policy
Stanford University
Redwood Bldg, T150A
Stanford, CA 94305-5405
Research Interests
outcomes research, clinical trials, cost-effectiveness
Mark Hlatky is a professor of Health Research and Policy and of medicine (cardiovascular medicine) at Stanford, as well as a CHP/PCOR fellow. His major interests are in outcomes research, evidence-based medicine, and cost-effectiveness analysis. He introduced data collection about economic and quality of life endpoints in several randomized trials, principally trials of therapies for cardiovascular disease.
Hlatky received his MD from the University of Pennsylvania, and, after residency at the University of Arizona, studied as a Robert Wood Johnson Clinical Scholar at the University of California, San Francisco. He trained in cardiology at Duke University Medical Center, and then joined the Duke faculty. He has been at the Stanford University School of Medicine since 1989, where he is currently professor and chair of Health Research and Policy.
Stanford Departments
Health Research and Policy
Publications
The 5 most recent are displayed. More publications »
Review: Rosiglitazone Increases Risk of MI But Does Not Differ from Other Drugs for CV Death in Type 2 Diabetes
Mark A. Hlatky, Dena M. Bravata
Evidence-Based Medicine vol. 12 (2007)
Systematic Review: The Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Graft Surgery
Dena M. Bravata, Allison Gienger, Kathryn M. McDonald, Vandana Sundaram, MV Perez, R Varghese, JR Kapoor, R Ardehali, Douglas K. Owens, Mark A. Hlatky
Annals of Internal Medicine vol. 147, 10 (2007)
Systematic Review: The Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Surgery
Dena M. Bravata, Allison Gienger, Kathryn M. McDonald, Vandana Sundaram, MV Perez, R Varghese, JR Kapoor, R Ardehali, Douglas K. Owens, Mark A. Hlatky
Annals of Internal Medicine (2007)
Rosiglitazone Increased Heart failure But Did Not Differ from Metformin Plus Sulfonylurea for Other CV Outcomes at Interim Analysis
Mark A. Hlatky, Dena M. Bravata
American College of Physicians Journal Club vol. 147, 3 (2007)
Statin and Beta-Blocker Therapy and the Initial Presentation of Coronary Heart Disease
A Go, C Iribarren, M Chandra, PV Lathon, Stephen P. Fortmann, T Quertermous, Mark A. Hlatky
Annals of Internal Medicine vol. 144, 4 (2006)
Events & Presentations
Comparative effectiveness of angioplasty and surgery for treatment of coronary artery disease
September 24, 2008 Research in Progress Seminar
Mark A. Hlatky- Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Grafting for Coronary Artery Disease
January 31, 2007 Research in Progress Seminar
Mark A. Hlatky, Dena M. Bravata
presentation available
Analysis in Randomized Controlled Trials
January 11, 2006 Research in Progress Seminar
Mark A. Hlatky- Health Services Research 101: HSR and Clinical Trials--Quality of Life and Cost Data in Clinical Trials
July 24, 2002 Seminar
Mark A. Hlatky

